Prostate cancer remains the second leading cause of death among men in the United States.

Prostate cancer is most common in men over 50 years of age..

Prostate cancer usually grows very slowly, and the disease may not manifest itself until the advanced stages, according to Pannochka, an online publication for girls and women aged 14 to 35.. net Most men with prostate cancer die from other causes before the cancer kills them. Sometimes they don't even know they have a disease..

But if prostate cancer turns out to be highly malignant and grows rapidly, then it is very dangerous..

Docetaxel - 10 years on the US market.

Exactly ten years ago, the FDA approved docetaxel, the first chemotherapy drug for the treatment of metastatic prostate cancer, which significantly improved survival.

The FDA approved docetaxel in 2004, after several years of unsuccessful searches for a drug that could prolong life in patients with metastatic prostate cancer..

“When prostate cancer spreads to other parts of the body, it becomes untreatable in most cases.. And then the goal of therapy will be to alleviate the symptoms of the disease and prolong the life of the patient,” explains Dr. Paul Kluetz (Paul Kluetz), current director of the CDER FDA Division of Oncology and Hematology Products..

Since docetaxel, five more drugs have been approved, and each of them increases the life expectancy of prostate cancer patients.. Dr. Kluetz says this is an unprecedented breakthrough - half a dozen drugs that extend the life of patients with metastatic cancer.

And although the average increase in life expectancy for each of these drugs is 2-6 months, it is hoped that with consistent use of drugs, the effectiveness of treatment will be higher.. In particular, due to the fact that they have different mechanisms of action. The optimal order and combinations are still unknown - this is an area for scientific research in the coming years..

Forward movement.

One area of \u200b\u200bclose interest for cancer researchers is prostate cancer, which has yet to metastasize.. Scientists are particularly interested in the selection criteria for patients who are at high risk of spreading cancer, and patients who can live with their tumor for many years without any treatment, only periodically taking tests..

In the United States, as in many other countries, prostate-specific antigen (PSA) testing has become widespread, thanks to which prostate cancer can be detected quite early.. But what to do next?

“We detect prostate cancer at an early stage thanks to the PSA test, but it does not give us additional information, for example, about the spread of cancer to other tissues.. Therefore, there is increased interest in new selection criteria. Some patients need immediate treatment, while others will die many years from natural causes, long before prostate cancer becomes a threat to them,” says Dr. Kluets.

Today, American scientists are actively working on the creation of molecular tests that will help identify high-risk patients.. These tests will help thousands of men avoid unnecessary prostate removal, radiation and severe chemotherapy side effects.. Meanwhile, evidence continues to mount for 'over- and unjustified' treatment of slow-growing prostate cancer..

Don't trust scammers!

As with most serious diseases, with prostate cancer, a lot of companies and clever businessmen fall on the head of a patient (especially a wealthy patient) who offer him "

"

Here are some examples of promises that scammers often use to advertise their products:.

•"

•“Treats benign prostatic hyperplasia”.

• "

• "

Agency experts say the effectiveness of products such as dwarf palm, beta-sitosterol, African plum and nettle has not been proven in due course.

medbe. en.